Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FERMT2 | Q96AC1 | 1/20 | 0.49 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.43 |
| ▸ | SOS2 | Q07890 | 1/20 | 0.43 |
| ▸ | GAK | O14976 | 1/20 | 0.42 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.41 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | GRM5 | P41594 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CCNC | P24863 | 1/20 | 0.38 |
| ▸ | CDK8 | P49336 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.37 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.37 |
| ▸ | AXL | P30530 | 1/20 | 0.37 |
| ▸ | PRKCI | P41743 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29691695 | 0.84 | CCNC (0.49) | FERMT2NR4A2GAKAAK1CYP1A2 | |
| SCHEMBL265444 | 0.84 | CCNC (0.49) | FERMT2NR4A2GAKAAK1CYP1A2 | |
| SCHEMBL317202 | 0.79 | NR4A2 (0.66) | FERMT2NR4A2SOS2CYP1A2MAPT | |
| SCHEMBL29396540 | 0.79 | NR4A2 (0.66) | FERMT2NR4A2SOS2CYP1A2MAPT | |
| Bromide SCHEMBL1611915 | 0.78 | NR4A2 (0.63) | FERMT2NR4A2SOS2CYP1A2MAPT | |
| SCHEMBL4655567 | 0.78 | AXL (0.42) | FERMT2NR4A2SOS2CYP1A2MAPT | |
| Bromide SCHEMBL1611919 | 0.78 | NR4A2 (0.63) | FERMT2NR4A2SOS2CYP1A2MAPT | |
| Hydrochloric Acid SCHEMBL11519956 | 0.78 | NR4A2 (0.63) | FERMT2NR4A2SOS2CYP1A2MAPT | |
| SCHEMBL4619603 | 0.76 | FERMT2 (0.49) | FERMT2GAKGRM4AAK1L3MBTL1 | |
| SCHEMBL16010398 | 0.76 | FERMT2 (0.49) | FERMT2NR4A2SOS2GAKGRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 124 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119241502-B | NSD3 degradation agent and preparation method and application thereof | 四川大学华西医院 | 2025-02-28 | — | — | CN | claimed |
| CN-119241502-A | NSD3 degradation agent and preparation method and application thereof | 四川大学华西医院 | 2025-01-03 | — | — | CN | claimed |
| US-12612384-B2 | Heterocyclic CYP4A inhibitor compounds and compositions thereof | MBD Co., Ltd. (KR) | 2026-04-28 | — | — | US | disclosed |
| US-12522595-B2 | Bicyclic ether O-glycoprotein-2-acetamido-2-deoxy-3-D-glucopyranosidase inhibitors | BIOGEN MA INC. (US) | 2026-01-13 | — | — | US | disclosed |
| US-12479821-B2 | Quinoline compound and use thereof | MBD Co., Ltd. (KR) | 2025-11-25 | — | — | US | disclosed |
| CN-119241502-B | NSD3 degradation agent and preparation method and application thereof | 四川大学华西医院 | 2025-02-28 | — | — | CN | disclosed |
| US-20250059157-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2025-02-20 | — | — | US | disclosed |
| CN-119241502-A | NSD3 degradation agent and preparation method and application thereof | 四川大学华西医院 | 2025-01-03 | — | — | CN | disclosed |
| US-20240360131-A1 | BIARYL KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2024-10-31 | — | — | US | disclosed |
| US-20240287032-A1 | NOVEL HETEROCYCLIC COMPOUND AND USE THEREOF | MBD Co., Ltd. (KR) | 2024-08-29 | — | — | US | disclosed |
| US-12065437-B2 | Biaryl kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2024-08-20 | — | — | US | disclosed |
| EP-1534681-A1 | SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-06-01 | — | — | EP | disclosed |
| US-20040132769-A1 | Certain phenylacetic acids and derivatives | NOVARTIS AG (CH) | 2004-07-08 | — | — | US | disclosed |
| WO-2004048314-A1 | SUBSTITUTED AMINO PHENYLACETIC ACIDS, DERIVATIVES THEREOF, THEIR PREPARATION AND THEIR USE AS CYCLOOXYGENASE 2 (COX-2) INHIBITORS | NOVARTIS AG (CH) | 2004-06-10 | — | — | WO | disclosed |
| US-20040072818-A1 | Substituted quinoline CCR5 receptor antagonists | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-04-15 | — | — | US | disclosed |
| WO-2004002960-A1 | SUBSTITUTED QUINOLINE CCR5 RECEPTOR ANTAGONISTS | SCHERING AKTIENGESELLSCHAFT (DE) | 2004-01-08 | — | — | WO | disclosed |
| EP-0326331-B1 | Substituted quinolines and cinnolines | DOW AGROSCIENCES LLC (US) | 2002-04-17 | — | — | EP | disclosed |
| US-5294622-A | Fungicides, insecticides, miticides | DOWELANCO (US) | 1994-03-15 | — | — | US | disclosed |
| US-5114939-A | Amine or ether substitutes compounds of quinoline or cinnoline | DOWELANCO (US) | 1992-05-19 | — | — | US | disclosed |
| EP-0326331-A2 | Substituted quinolines and cinnolines | DowElanco (US) | 1989-08-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240287032-A1 | NOVEL HETEROCYCLIC COMPOUND AND USE THEREOF | CYP4B1, CYP4A11, CYP3A4 | FERMT2 3657/4885NR4A2 91/4885SOS2 4144/4885 |
| US-12479821-B2 | Quinoline compound and use thereof | CYP4A11, CYP7A1, CYP4B1 | FERMT2 1658/4885NR4A2 132/4885SOS2 3523/4885 |
| US-12612384-B2 | Heterocyclic CYP4A inhibitor compounds and compositions thereof | CYP4A11, CYP4B1, CYP4A22 | FERMT2 4024/4885NR4A2 117/4885SOS2 2348/4885 |
| US-20040132769-A1 | Certain phenylacetic acids and derivatives | CYP2A6, HCAR2, CYP2B6 | FERMT2 4349/4885NR4A2 795/4885SOS2 4388/4885 |
| US-12065437-B2 | Biaryl kinase inhibitors | AAK1, NCK1, MARCKS | FERMT2 2067/4885NR4A2 2752/4885SOS2 1408/4885 |
| US-20250059157-A1 | TLR7/8 ANTAGONISTS AND USES THEREOF | TLR7, TLR8, TLR9 | FERMT2 3334/4885NR4A2 70/4885SOS2 3266/4885 |
| US-20040072818-A1 | Substituted quinoline CCR5 receptor antagonists | CCR5, CXCR3, CCR2 | FERMT2 3714/4885NR4A2 299/4885SOS2 1911/4885 |
| US-20240360131-A1 | BIARYL KINASE INHIBITORS | AAK1, NCK1, MARCKS | FERMT2 2067/4885NR4A2 2752/4885SOS2 1408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.